Clinical Trial Update: Safety Study of Subcutaneously Administered PL-3994 in Subjects With Controlled Hypertension [Phase 2]

View source ↗

Summary

Phase 2 safety study of subcutaneously administered PL-3994 in adults with controlled hypertension completed; results were posted in 2013.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Hypertension

Drugs mentioned

• PL-3994

Snippet

Sponsor: Palatin Technologies, Inc | Conditions: Hypertension | Phase 2 | Status: COMPLETED | Results posted: 2013-06-21